Chief Executive Officer
Mr. Genberg was previously Senior VP, R&D, Ceragenix Pharmaceuticals, where he successfully developed and licensed to Dr. Reddy’s Laboratories Ltd. Epiceram®, a controlled-release skin-barrier-repair emulsion that offers unique, non-steroidal therapy for patients with eczema and atopic dermatitis. Mr. Genberg was also previously Co-Founder, Board Member and Regulatory counsel to medical device company where he helped design and implement a clinical trial leading to PMA approval of lead product in 14 months and key advisor to the CEO, leading to $100 million IPO led by Goldman Sachs. Successful track record leading commercialization of biotechnology products, including 510(k) and PMA, managing clinical studies, establishing research networks and obtaining non-dilutive financing; co-inventor on multiple patents. Prior experience in early career as an attorney with extensive practice in intellectual property licensing transactions and issues and FDA regulatory matters.